~~<i id='E5D94CF63E'><strike id='E5D94CF63E'><tt id='E5D94CF63E'><pre id='E5D94CF63E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：Wikipedia 2025-09-03 05:34:11 - browse：28154

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： A solution to the after

leisure time

hotspot

entertainment

hotspot

LawmakersinCongresshavedecidedtopunteffortstoreformhowPBMsoperate.BRENDANSMIALOWSKI/AFP/GettyImagesW

WSS

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

A new nitrogen execution bill also undermines medical licensing

Amylyx ALS drug failure raises questions and concerns

Change Healthcare payments predicted restored March 15

STAT readers on older presidents, polypills, Medicare, and more

RSV shot was 90% effective at preventing hospitalizations in kids

hotspot

Wikipedia

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Community Health Systems hospitals under DOJ investigation

Trump demands the U.S. pay no more for drugs than other countries … again

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Walensky prepares to leave CDC — and Congress — behind

UnitedHealth quietly bought dozens of outpatient centers

Heart attack and stroke risk calculators need revising

A deep dive into Applied Therapeutics’ data, and questions on Cassava

How to save PrEP access — and even expand it

With competition flaring, obesity drug hits goal in liver disease study

hotspot

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Change Healthcare payments predicted restored March 15

6 phony surgeries that take placebo to the extreme

Obesity drugs seen as possible treatment for liver disease MASH

STAT readers on older presidents, polypills, Medicare, and more

entertainment

hotspot

hotspot

hotspot